Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Annexin Pharmaceuticals AB: BioStock: Annexin: Could ANXV replace anti-VEGFs?

Annexin Pharmaceuticals

Annexin Pharmaceuticals is developing the drug candidate ANXV in the eye disease retinal vein occlusion, RVO, as well as in cancer. Recently, the company released phase IIa topline results from its study in RVO. Annexin visited BioStock's studio to talk more about the results and the plan going forward.
- The results are as good as we could have ever hoped for, says CEO Anders Haegerstrand.

Watch the interview with CEO Anders Haegerstrand and CMO/CSO Anna Frostegård at biostock.se:
https://www.biostock.se/en/2024/08/annexin-pharmaceuticals-could-anxv-replace-anti-vegfs/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.